Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia

Abroad (travel likely)RecruitingPHASE2, PHASE3

Conditions

Achondroplasia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • UCSF Benioff Children's Hospital Oakland, Oakland, California, United States

    Contact: Study coordinator (Hind Al-Saif)
  • Nemours Children's Health, Wilmington, Delaware, United States

    Contact: Study coordinator (Mahim Jain)
  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

  • Johns Hopkins Medicine, Baltimore, Maryland, United States

    Contact: Study coordinator (Julie Hoover-Fong)
  • Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

    Contact: Study coordinator (Benjamin Cocanougher)
  • Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

    Contact: Study coordinator (David Weber)
  • University of Texas Southwestern Medical Center, Dallas, Texas, United States

    Contact: Study coordinator (Nadia Merchant)
  • Texas Children Hospital, Baylor College of Medicine, Houston, Texas, United States

    Contact: Study coordinator (Carlos Bacino)
  • Consano Clinical Research, LLC, San Antonio, Texas, United States

    Contact: Study coordinator (Daniel Katselnik)
  • Murdoch Children's Research Institute, Parkville, Victoria, Australia

    Contact: Study coordinator (Ravi Savarirayan)
  • Universite de Montreal - Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada

    Contact: Study coordinator (Philippe Campeau)
  • Irccs Ospedale Gaslini Di Genova, Genova, Italy

    Contact: Study coordinator (Mohamed Maghnie)
  • Uniwersytecki Szpital Kliniczny im. J. Mikulicza-Radeckiego we Wroclawiu Klinika Pediatrii i Chorob Infekcyjnych, Wroclaw, Poland

    Contact: Study coordinator (Robert Shanislaw Smigiel)
  • Institutul National de Endocrinologie C.I.Parhon, Bucharest, Romania

    Contact: Study coordinator (Iuliana Gherlan)
  • Craiova Emergency Clinical County, Craiova, Romania

    Contact: Study coordinator (Ioana Streata)
  • Seoul National University Hospital, Seoul, South Korea

  • Pusan National University Yangsan Hospital, Yangsan, South Korea

    Contact: Study coordinator (Chong-Kun Cheon)
  • University Hospitals Bristol NHS Foundation Trust - Bristol Royal Hospital for Children, Bristol, United Kingdom

    Contact: Study coordinator (Toby Candler)
Study leads
  • Medical Director, PhD

    Study Director

    BioMarin Pharmaceutical